Exchange & Returns Information
Review Details
(32)
| Drug Type | Original |
|---|---|
| Active Ingredient | GOSERELIN |
| Strength | 3.6MG |
| Manufacturer | ASTRA ZENECA |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 VIAL | $ 103.30 | $ 103.30 |
$ 87.80
Apply ZARVY26 (-15%)
You save $ 15.50
|
||
| 2 BOXES - 2 VIALS | $ 103.80 | $ 207.60 |
$ 176.46
Apply ZARVY26 (-15%)
You save $ 31.14
|
||
| ★ Best Value 3 BOXES - 3 VIALS | $ 106.97 | $ 320.90 |
$ 272.77
Apply ZARVY26 (-15%)
You save $ 48.14
|
Reference information will be available soon.
Zoladex 3.6 is a subcutaneous depot injection containing goserelin 3.6mg, a synthetic analogue of gonadotropin-releasing hormone (GnRH). It provides reversible suppression of the hypothalamic-pituitary-gonadal (HPG) axis by initially stimulating, then downregulating, GnRH receptors. This leads to profound reductions in circulating sex hormones such as testosterone in men and estrogen in women, effectively mimicking the effects of surgical castration. Zoladex 3.6 is used in the palliative management of advanced prostate cancer and hormone receptor-positive breast cancer in premenopausal women. It is also indicated in several gynecologic conditions including endometriosis, uterine fibroids, and for ovulation suppression in assisted reproductive technologies like IVF. With its monthly dosing schedule and proven clinical efficacy, Zoladex 3.6 remains a cornerstone in hormone-sensitive oncologic and gynecologic therapy.
- AntiCancer Drugs > Prostate Cancer Used as a first-line hormonal therapy in patients with advanced or metastatic prostate cancer. It reduces testosterone levels to castrate range, slowing tumor progression and relieving disease-related symptoms. Zoladex 3.6 offers a monthly formulation for consistent suppression. > HR+ Breast Cancer in Premenopausal Women Indicated in hormone receptor-positive breast cancer in pre- or perimenopausal women for ovarian suppression. It is frequently combined with aromatase inhibitors to induce functional menopause and enhance endocrine treatment efficacy. - Hormones & Menopausal Symptoms - FEMTECH > Endometriosis Used to alleviate pelvic pain and reduce endometrial lesions by inducing a hypoestrogenic state. Goserelin provides a temporary and reversible menopause-like hormonal environment for symptom relief. > Uterine Fibroid Prescribed preoperatively to shrink fibroid size and reduce uterine bleeding. It facilitates surgical intervention and improves hemoglobin levels in anemic patients. > Ovulation Suppression in IVF Employed in fertility protocols to prevent premature luteinizing hormone (LH) surges during ovarian stimulation. Helps synchronize follicular development and improve oocyte retrieval outcomes in IVF cycles.
Goserelin acts by continuously stimulating GnRH receptors in the anterior pituitary, leading to receptor desensitization and decreased secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in suppressed production of sex hormones—testosterone in males and estradiol in females. In prostate cancer, this chemical castration effect slows disease progression. In hormone receptor-positive breast cancer, it limits tumor growth driven by estrogen. Goserelin also helps manage estrogen-dependent conditions like endometriosis and fibroids by creating a reversible hypoestrogenic state. The depot formulation ensures consistent hormone suppression over a 28-day period with a single subcutaneous injection.
Prostate Cancer (Advanced, Palliative): → 3.6 mg subcutaneously every 28 days OR → 10.8 mg subcutaneously every 12 weeks → Continue long-term unless contraindicated → Used to maintain castrate-level testosterone in advanced prostate carcinoma Prostate Cancer (Locally Confined, Radiotherapy + Flutamide): → Option 1: 3.6 mg once, then 10.8 mg after 28 days → Option 2: 3.6 mg every 28 days for 4 doses (2 pre-, 2 during radiation) → Used as neoadjuvant and concurrent hormonal therapy (T2b–T4 disease) Endometriosis: → 3.6 mg subcutaneously every 28 days → Recommended duration: 6 months → Effective in reducing pain, dysmenorrhea, and lesion size Breast Cancer (Premenopausal, HR+): → 3.6 mg subcutaneously every 28 days → Long-term administration unless treatment is changed → Used with aromatase inhibitors or as monotherapy in palliative settings Endometrial Thinning (Prior to Ablation): → 3.6 mg once OR → 3.6 mg twice, 4 weeks apart → Perform surgery 4 weeks after the last dose → Helps optimize surgical outcomes by reducing endometrial thickness Administration Tips: → Administer subcutaneously into the anterior abdominal wall → Use implant injection device provided with the product → Do not withdraw or alter implant once inserted → Ensure proper supplementation if used long-term (e.g., calcium, vitamin D)
Store below 25°C in a dry place. Do not freeze. Protect from direct light and humidity. Use the injection immediately after opening the pouch. Keep out of reach of children.
Common: hot flashes, decreased libido, injection site reactions, sweating, mood changes Less Common: breast tenderness, headache, acne, insomnia, irregular bleeding (females) Rare: osteoporosis, cardiovascular events, glucose intolerance, tumor flare Seek medical attention if symptoms like bone pain, chest discomfort, or sudden mood shifts occur.
I appreciated being able to choose the payment method that worked best for me.
Customs sometimes worry me, but adding insurance made me confident.
Exactly what I ordered.
Simple order, no issues.
咨询后很快得到答复，服务令人满意。
No combo deals available at the moment.
